New drug may get your gut moving faster after hernia repair
NCT ID NCT05985343
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether sugammadex, a drug used to reverse muscle relaxants after surgery, could help patients regain bowel function faster than standard care. 184 adults undergoing open abdominal wall reconstruction for ventral hernia were randomly assigned to receive either sugammadex or the usual reversal drugs. The main goal was to see how quickly patients could eat solid food and have their first bowel movement after surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- sugammadex
- What this could lead to
- If it works, sugammadex could help patients recover bowel function faster after abdominal wall surgery, reducing hospital stays.
- What could go wrong
- This is a small, completed Phase 4 trial with 184 patients, so results may not apply to everyone. Sugammadex can cause allergic reactions in some people.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
184 people
The number who actually took part.
- Started
-
Jan 2024
- Finished
-
Jun 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults \>18 years old * Patients requiring an open ventral hernia repair with retromuscular mesh placement and at least one myofascial advancement flap * Hernias with fascial defects \< 20cm wide * Non-emergent cases Exclusion Criteria: * Known serious or severe hypersensitivity reaction to sugammadex or any of the ingredients in sugammadex. * Hernias with fascial defects \> 20cm wide * Concomitant treatment with a strong or moderate cytochrome P450 3A4 inhibitor (e.g., Ketoconazole and other anti-fungals, Clarithromycin, HIV protease inhibitors, diltiazem, erythromycin, verapamil) or strong CYP3A4 inducers (e.g., rifampin). * Known small bowel obstruction (SBO) at the time of hernia repair * Suspected SBO or at risk of recurrent SBO at the time of hernia repair - at the discretion of the staff surgeon. * Nasogastric (NG), orogastric (OG), or gastric (eg. PEG) in place at the time of hernia repair and left in beyond the morning of the first postoperative day. * Patients with a stoma. * Cancer with increased risk of gastro-duodenal perforation (e.g., infiltrative gastrointestinal tract malignancy, recent gastrointestinal tract surgery, diverticular disease including diverticulitis, ischemic colitis, or concomitantly treated with bevacizumab) - at the discretion of the staff surgeon. * Disorder that could alter the integrity of the gastrointestinal lining (e.g., Crohn's disease) - at the discretion of the staff surgeon. * Severe hepatic failure (Child-Pugh Class C). * Clinically relevant hepatic failure (e.g. cirrhosis) - at the discretion of the staff surgeon. * Severe renal failure (GFR\<30ml/min, on dialysis, or have an arteriovenous fistula, indwelling hemodialysis catheter or peritoneal dialysis catheter) - at the discretion of the staff surgeon. * Pregnant or planning to become pregnant during study period. * Breastfeeding or planning to breastfeed during study period. * Clinically relevant alteration of the blood-brain-barrier - at the discretion of the staff surgeon. * Other contraindication to sugammadex as documented by a physician. * Unable to give informed consent; vulnerable populations; non-English speaking. * Emergent operation. * Undergoing minimally invasive approaches. * Undergoing repair with mesh placed in a position other than retromuscular. * Chronic opioid users, as defined by the daily use of opioids for at least 90 days within the past year * Inability to safely extubate the patient at the end of the surgery for any reason, as determined by the operative team.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hernia, ventral are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic Center for Abdominal Core Health
Cleveland, Ohio, 44195, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'Teach-Back' approach boost confidence and ease anxiety after ostomy surgery?
- Smartphone Follow-Up could replace hospital stays after common surgeries
- New Self-Gripping mesh aims to reduce hernia recurrence in High-Risk patients
- Muscle relaxation study for hernia surgery halted before starting
- Simple surgical stitch may prevent dangerous bowel blockage after rectal cancer surgery
- New strategy aims to prevent breathing trouble after hernia repair